This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024
December 15 - 18, 2024
Marriott Marquis San Diego,
Live In-Person Event: December 15 - 18, 2024

Antibody Engineering & Therapeutics US's 2021 Preliminary Agenda

Returning in person, with the option to also attend virtually, the 2021 preliminary agenda is here

Download the agenda to find out what is on offer

Confirmed Antibody Engineering & Therapeutics US Speakers and Presentations for 2021


Workshop A: Machine Learning for Antibody and Protein Engineering 
Workshop Moderator:
Derek Mason, Ph.D., Director of Operations, deepCDR Biologics, Switzerland

Workshop B: When High Affinity Is Necessary in Antibody Therapeutics 
Workshop Moderator:
Stephen Parmley, Ph.D., Vice President, Molecular Biology & Protein Sciences, AnaptysBio


Engineered Cytokines for Cancer Immunotherapy Sessions

Session Chairs:
Paul J. Carter, Ph.D., Genentech Fellow, Department of Antibody Engineering, Genentech, Inc.
Jonathan Sockolosky, Ph.D., Scientist, Department of Antibody Engineering, Genentech

IL-18 for Cancer Immunotherapy
Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology, Yale School of Medicine

Engineered IL-2 Variants
Andy Yeung, Ph.D., Chief Technology Officer, Asher Biotherapeutics

Engineering Tumor-Tropic Cytokines for Cancer Immunotherapy
Jeffrey Hubbell, Ph.D., Eugene Bell Professor in Tissue Engineering, The University of Chicago

Tripokin: A Potency-matched Dual Cytokine Fusion for Cancer Therapy
Dario Neri, Ph.D., CEO and CSO, Philogen, Switzerland 

Applications of Engineered Cytokines in Cancer Immunotherapy
Shannon Turley, Ph.D., Senior Director, Genentech

Discovery of Tumor Targeting IL2Rb Agonist by mRNA Display Enabled Technology Platforms
Yan Chen, Ph.D., Founder & Chief Executive Officer, Elpis Biopharmaceuticals

A Bispecific Antibody Agonist of The IL-2 Heterodimeric Receptor Promotes In Vivo Expansion Of CD8 And NK Cells
Katherine Harris, Ph.D., Vice President, Discovery, TeneoBio

Engineering the Fc Region for Therapeutics Sessions

Session Chairs:
Sally Ward, Ph.D., Professor and Director, University of Southampton, United Kingdom
Robert de Jong, Ph.D., Director Antibody Research & Technology, Genmab, The Netherlands

Fc Engineering to Create Mutually Dependent Antibody Combinations
Robert de Jong, Ph.D., Director Antibody Research & Technology, Genmab, The Netherlands

Tafasitamab, An FcgR-enhanced Antibody to Treat B Cell Lymphoma
Martin Steegmaier, Ph.D., Senior Vice President and Head of Research, MorphoSys, Germany

Afucosylated IgG responses in health and disease: Friend or foe?
Gestur Vidarsson, Ph.D., Head of Immunoglobulin Research/PI, Experimental Immunohematology, Sanquin Research, The Netherlands

Fc-mediated Effector Functions in Anti-viral Responses
Margaret Ackerman, Ph.D., Professor of Engineering, Dartmouth College

Engineered IgA to Activate Neutrophils and MDSC for Cancer Therapy
Jeanette Leusen, Ph.D., Associate Professor, Head Immunotherapy Group and UMAB Facility, Laboratory for Translational Immunology, University Medical Center Utrecht

Treatment of Antibody-mediated Autoimmunity with Efgartigimod
Sophie Steeland, Ph.D., Senior Clinical Scientist, argenx, Belgium

Innovative Targets for Antibody-based Therapies Sessions

Session Chair:
James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

Engineering Targeted Antibody Therapeutics Against Multi-drug Resistant Bacterial Infections
Jamie Spangler, Ph.D., Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Johns Hopkins University

Targeting NEDD9 to Inhibit Platelet-endothelial Adhesion and Pulmonary Thrombosis
Bradley Maron, M.D., Associate Professor of Medicine, Harvard Medical School

GDF15 Story
Bo Yu, Ph.D., Co-founder and Chief Scientific Officer, Larix Bioscience LLC

C9orf 72 ALS-FTD Story
Dieter Edbauer, M.D., Professor, Cell Biology of Neurodegeneration, DZNE, Germany

Kirk Essenmacher, M.D., CEO, Triursus Therapeutics

Therapeutic Antibody Targeting of APOE-HSPG Interactions in Alzheimer’s Disease
Joseph Arboleda-Velasquez, M.D., Ph.D., Assistant Professor of Ophthalmology, Harvard Medical School

Single Domain Antibodies: Repertoire, Engineering and Applications Sessions

Session Chair:
Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI

Human Antibody Domains As Therapeutics Against Viruses and Cancer
Dimiter Dimitrov, Ph.D., Professor and Director, Center for Antibody Therapeutics (CAT), University of Pittsburgh Medical School and Chief Scientific Officer, Abound Bio

Camel and Shark Single Domain Antibodies Targeting Cancer and Viral Antigens
Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI

Development of Nanobodies as Drugs
Carlo Boutton, Ph.D., Global Head Innovation, Large Molecule Research Platform, Sanofi, Belgium

Chicken Heavy Chain Antibodies to SARS-CoV-2 Spike Protein
Phil Leighton, Ph.D., Senior Director of Molecular Biology, Ligand Pharmaceuticals

Envafolimab: A Single Domain PD-L1 Antibody Given by Rapid Subcutaneous Injection That Is Being Studied in Pivotal Trials in the US and China
Charles Theuer, M.D., Ph.D., Director, President and CEO, Tracon Pharmaceuticals

Designing Ankyrin Repeat Proteins (DARPins) As Single Domains
Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland (Invited)

When High Affinity Is Necessary in Antibody Therapeutics Sessions

Session Chair:
Stephen Parmley, Ph.D., Vice President, Molecular Biology & Protein Sciences, AnaptysBio

nAbs Against SARS-CoV2 with Higher Affinity by SPR Correlate with Better Neutralization of the Virus in Vitro
Joseph Jardine, Ph.D., Director of Product Discovery and Optimization, International AIDS Vaccine Initiative

Affinity Maturation of Antibodies by Combinatorial Codon Mutagenesis Versus Error-prone PCR
Jan Simons, Ph.D., Senior Director, Technology, GigaGen

Anti-BCMA and Anti-CD3 Bispecifics Showing Higher Affinity Variants Were More Potent
Javier Chaparro-Riggers, Ph.D., Executive Director, Pfizer

Practical Utility of Repertoire Data for Antibody Affinity Maturation
Luke Burman, Senior Scientist, aTyr Pharma

Targeting Challenging Protein Targets Using Conformationally Selective Antibodies
Charles S. Craik, Ph.D., Professor, Department of Pharmaceutical Chemistry, UCSF

Next Wave of Immuno-oncology Therapeutic Antibodies Sessions

Session Chair:
Jennifer Cochran, Ph.D., Professor and Department Chair of Bioengineering, Stanford University

Improved Therapeutic Index to CTLA4 with An Acidic pH-selective Antibody
Peter Lee, Ph.D., Principal Scientist, Bristol Myers Squibb

Hard Targets in Cancer Therapeutics: Engineering a Next Generation Anti-VISTA Antibody
Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer and Co-Founder, Hummingbird Bioscience

A Novel Platform for Next-generation T-cell Bispecific Antibody
Shun Shimizu, Researcher, Chugai Pharmaceutical co., ltd., Japan

Advancement of MATCH Antibodies to Clinical-stage: Novel Therapeutics with Tumor Targeted Immunomodulatory Functions and the Potential for Favorable Benefit-risk Profiles
Tea Gunde, Vice President, Discovery, Ph.D., Numab Therapeutics AG, Switzerland

Anti-GD2 Antibodies Block GD2:Siglec-7 Interactions and Synergize with Anti-CD47 to Mediate Tumor Clearance in Neuroblastoma and Other GD2+ Malignancies
Robbie Majzner, M.D., Assistant Professor, Pediatrics - Hematology & Oncology, Stanford

IgM Antibodies
Kathy Miller, Ph.D., Vice President. Antibody Discovery, IGM Biosciences

Learnings and Challenges in Immune Cell Recruitment Strategies Using Bispecific Antibodies Sessions 

Session Chairs:
Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and EVP and Head of R&D, Lava Therapeutics, The Netherlands

Katherine Harris, Ph.D., Vice President, Discovery, TeneoBio

Combination Immunotherapy with CAR T cells and Bispecific Antibodies
Bryan Choi, M.D., Ph.D., Brain Tumor Surgeon, Department of Neurosurgery, Massachusetts General Hospital/Harvard

Mitigating Cytokine Release with Novel Low Affinity Anti-CD3 based T-Cell Engagers
Udaya S. Rangaswamy, Ph.D., Senior Scientist, Teneobio

Mechanisms of Tcell Engagers 
Brian Belmontes, Senior Scientist, Oncology Department, Amgen (Invited)

Bispecific Antibodies Targeting Mutant RAS Neoantigens
Emily Hsiue, M.D., Scientist, Johns Hopkins University (Invited)

Novel DARPin® Approaches for the Development of T-cell Engagers with Improved Safety and Efficacy
Christian Reichen, Ph.D., Associate Director Oncology Research, Molecular Partners AG, Switzerland

Progression of Innovative Antibody-based Therapeutics to Clinical Stage Sessions
Session Chairs:
Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands

James A. Ernst, Ph.D., Senior Director, Head of Development Sciences, Xencor

Xencor B7H3 x CD28 Program
Gregory Moore, Ph.D., Director, Protein Engineering, Xencor

DuoHexaBody-CD37: Translating Antibody Engineering into Therapeutic Applications
Simone Oostindie, Scientist, Early Stage Translational Research, Genmab, The Netherlands

IMA401 & IMA402: Alternatively Formatted CD3 bsAbs against MHCp
Dominik Maurer, M.D., Vice President, Immunology, Immatics Biotechnologies GmbH, Germany

NK Cell Engagers
Eric Vivier, Ph.D., SVP and Chief Scientific Officer, Innate Pharma, France

Improved Brain Delivery of Antibodies with Enhanced Binding to FcRn at Neutral pH
Jasi Atwal, Ph.D., Scientist, Neuroscience, Genentech

Machine Learning for Antibody and Protein Engineering Sessions

Session Chairs:
Derek Mason, Ph.D., Director of Operations, deepCDR Biologics, Switzerland

Sai Reddy, Ph.D., Associate Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

Deep Learning for Immunoglobulin Modeling and Design
Possu Huang, Ph.D., Assistant Professor of Bioengineering, Stanford University

Exploring Protein Fitness Landscapes Using Machine Learning
Katya Putintseva, Ph.D., Data Scientist, LabGenius

Deep Generative Models for Protein Design and Variant Prediction
Debora Marks, Ph.D., Assistant Professor of Systems Biology, Harvard Medical School

CDRH3 Structure Prediction Using Deep Learning
Jeffrey Gray, Ph.D., Professor, Chemical & Biochemical Engineering, Johns Hopkins (Invited)

Sequence based Prediction of An Antibody’s Biophysical Properties Using Machine Learning
Tushar Jain, Ph.D., Principal Scientist, Adimab (Invited)

Vaccines and Antibodies to SARS-CoV-2: Dealing with Antigenic Variation Sessions 

Session Chair:

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbiology, The Scripps Research Institute

Structural Insights on Antigenic Variation of SARS-CoV-2 Spike for Antibody Recognition
Ian Wilson, D.Phil, Hansen Professor of Structural Biology and Chair Department of Integrative Structural and Computational Biology California Campus, Scripps Research

Intratumoral Immunotherapy Administration Sessions
Session Chair:
K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Targeted Drug Conjugates Sessions 

Session Chairs:
Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology and Peter Senter, Ph.D., VP, Distinguished Research Fellow, Seattle Genetics

Targeted Nanoparticle Drug Conjugates for the Treatment of Cancer
Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology

Advances with CAR-effectors Sessions
Session Chairs:
Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London

Shimobi Onuoha, Ph.D., Head, Protein Engineering, Autolus Limited, United Kingdom

Rethinking Allogeneic CAR T Therapies
David Gilham, Ph.D., Chief Scientific Officer, Celyad S.A., Belgium

Novel Engineered Tuneable CARs Using Single Domain Antibody Modalities
Mathieu Ferrari, Ph.D., Director - Binder Discovery, Autolus Ltd., United Kingdom

High-Throughput Antibody Discovery and Engineering: Driving Innovation Towards 0-day Discovery Sessions 

Session Chair:
Jean-Philippe Bürckert, Ph.D., Director, Bioinformatics, Large Molecule Discovery, Charles River Laboratories

Antibody Library Design, Selection and Screening Sessions
Session Chair:
Andrew Bradbury, M.D., Ph.D., Chief Scientific
Officer, Specifica

Presentation Title TBA
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Antibody Repertoires and COVID-19 Sessions
Session Chair:
Nina Luning Prak, M.D., Ph.D., Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania

Tracking Expanded B Cell Clones through Tissues and Over Time in the Era of COVID
Nina Luning Prak, M.D., Ph.D., Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania